Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer
National Institute for Clinical Excellence
Record ID 32003000501
English
Authors' objectives:
To provide guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer.
Authors' recommendations:
Guidance:
1.1 In the treatment of locally advanced or metastatic breast cancer, capecitabine in combination with docetaxel is recommended in preference to single-agent docetaxel in people for whom anthracycline-containing regimens are unsuitable or have failed.
1.2 Capecitabine monotherapy is recommended as an option for people with locally advanced or metastatic breast cancer who have not previously received capecitabine in combination therapy and for whom anthracycline and taxane-containing regimens have failed or further anthracycline therapy is contraindicated.
1.3 The decision regarding treatment should be made jointly by the individual and the clinician(s) responsible for treatment. The decision should be made after an informed discussion between the clinician(s) and the patient; this discussion should take into account contraindications and the side effect profile of the agents, alternative treatments for locally advanced or metastatic breast cancer, and the clinical condition and preferences of the individual.
1.4 The use of capecitabine to treat locally advanced or metastatic breast cancer should be supervised by oncologists who specialise in breast cancer.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.nice.org.uk/cat.asp?c=70089
Year Published:
2003
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antimetabolites, Antineoplastic
- Breast Neoplasms
- Deoxycytidine
- Prodrugs
Contact
Organisation Name:
National Institute for Clinical Excellence
Contact Address:
MidCity Place, 71 High Holborn, London WC1V 6NA, UK. Tel: +44 020 7067 5800; Fax: +44 020 7067 5801
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.